Enzo Biochem

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which engages in the manufacture, development and market of products and tools for clinical research, translational research, drug development and bioscience research. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in August 1976 and is headquartered in New York, NY.

Enzo Biochem (NYSE: ENZ ) stock is rocketing higher on Friday after the company agreed to an asset sale with Labcorp (NYSE: LH ). That asset sale has Enzo Biochem agreeing to divest its Clinical Laboratory division to Labcorp.

Why Is Enzo Biochem (ENZ) Stock Up 72% Today?

Significant value unlocked for Enzo shareholders with continued focus on remaining businesses.

Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp

Enzo Biochem, Inc. (NYSE:ENZ ) Q1 2023 Earnings Conference Call December 13, 2022 8:30 AM ET Company Participants Unidentified Company Representative - IR Hamid Erfanian - CEO Patricia Eckert - Interim CFO Conference Call Participants Operator Greetings and welcome to the Enzo Biochem, Incorporated First Quarter 2023 Earnings Call. At this all participants are in a listen-only mode.

Enzo Biochem, Inc. (ENZ) Q1 2023 Earnings Call Transcript

- Enzo Life Sciences reports revenue of $7.1 million and 9% growth in Q1 FY 2023, excluding FX

Enzo Biochem Reports First Quarter Fiscal Year 2023 Financial Results and Provides Business Update

Conference Call and Webcast Scheduled for December 13 th , 8:30 AM ET

Enzo Biochem, Inc. to Report First Quarter Fiscal 2023 Financial Results and Business Update on Monday, December 12th

NEW YORK, NY, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that its Annual Shareholders' Meeting will be held on January 31, 2023.  Shareholders must submit proposals and/or director nominations in connection with meeting no later than November 18, 2022 to be considered timely.

Enzo Biochem, Inc. Announces Date of Annual Shareholders' Meeting

- David Bench resigning to pursue a new career opportunity - - David Bench resigning to pursue a new career opportunity -

Enzo Biochem, Inc. Appoints Patricia Eckert, CPA as Interim CFO

- Enzo Life Sciences reports revenue of $32.6 million and 8% growth in FY 2022, net of FX

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

Conference Call and Webcast Scheduled for October 1 4 , 202 2 , 8 : 3 0 a m ET

Enzo Biochem to Report Fourth Quarter 2022 Financial Results and Business Update on Friday, October 14th

Powered by Enzo's LoopRNA™ ISH technology, a new platform designed for superior sensitivity in detection and visualization of biomarkers in the spatial context of cells and tissues Powered by Enzo's LoopRNA™ ISH technology, a new platform designed for superior sensitivity in detection and visualization of biomarkers in the spatial context of cells and tissues

Enzo Biochem, Inc. Launches AMPIVIEW™ Gene Expression Platform with First Products Targeting Detection of HPV and SARS-CoV-2

NEW YORK, NY, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced today that its full-service clinical laboratory will begin accepting specimens for monkeypox (MPX) testing this week.

Enzo Biochem to Launch Monkeypox Testing Services this Week

Enzo Biochem, Inc. (NYSE:ENZ ) Q3 2022 Earnings Conference Call June 10, 2022 8:30 AM ET Company Participants Chris Calabrese - Investor Relations Hamid Erfanian - Chief Executive Officer David Bench - Chief Financial Officer Conference Call Participants J. P. Sullivan - Potomac Capital Operator Greetings and welcome to the Enzo Biochem Third Quarter 2022 Financial Results and Business Update.

Enzo Biochem, Inc. (ENZ) CEO Hamid Erfanian on Q3 2022 Results - Earnings Call Transcript

Conference call and live webcast scheduled for tomorrow, Friday, June 10, 2022 at 8:30 am (ET)

Enzo Biochem Reports Third Quarter Fiscal 2022 Results and Provides Leadership and Corporate Updates Including Engagement of Jefferies as Financial Advisor

Conference Call and Webcast Scheduled for June 10, 2022, 8:30 am ET Conference Call and Webcast Scheduled for June 10, 2022, 8:30 am ET

UPDATE -- Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th

Conference Call and Webcast Scheduled for June 9, 2022, 4:30 pm ET

Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th

Meeting Scheduled for April 8, 2022 at 9:00 AM ET

Enzo Biochem Adjourns Annual Meeting of Shareholders to Complete Vote on Proposal

NEW YORK, NY, April 01, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced its 2021 Annual Meeting of Shareholders (“Annual Meeting”), with respect to Proposal 1, has been adjourned until April 8, 2022 at 9 AM EDT.

Enzo Biochem Adjourns Annual Meeting of Shareholders Until April 8, 2022

NEW YORK, NY, March 28, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced two key appointments to its new management structure. The Company announced Kara Cannon has been named Chief Operating Officer from her previous role as Chief Commercial Officer and David Bench, current Chief Financial Officer, has been named to the additional roles of Senior Vice President, Treasurer, and Corporate Secretary, effective immediately. Enzo is actively engaged in a search to augment its executive team including adding a Vice President of Commercialization, Director of Regulatory Affairs, Director of Research & Development, and General Counsel.

Enzo Biochem Appoints David Bench and Kara Cannon to New Executive Management Positions

Enzo Biochem, Inc. (ENZ) CEO Hamid Erfanian on Q2 2022 Results - Earnings Call Transcript

Conference call and live webcast scheduled for today, Monday, March 14, 2022 at 4:30 pm (ET)

Enzo Biochem Reports Second Quarter Fiscal 2022 Result and Provides Leadership and Corporate Updates

NEW YORK, NY, March 10, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ), a leading biosciences and diagnostics company, today announced that management will present at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum, Tuesday, March 22, 2022 at 3:00pm Eastern Time. The format will be a "fireside chat" discussion hosted by KeyBanc's Research Analyst Paul Knight.

Enzo Biochem to Present at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum

Conference Call and Webcast Scheduled for March 14, 2022, 4:30 pm ET

Enzo Biochem to Report Second Quarter 2022 Financial Results and Business Update on Monday, March 14th

NEW YORK, NY, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the appointments of Hamid Erfanian and Bradley Radoff to the Company's Board of Directors (the “Board”), effective immediately. The Company also announced that directors Dov Perlysky and Rebecca Fischer will step down from the Board immediately to facilitate a smooth transition for the new Board members. Dr. Mary Tagliaferri will become the Board's lead independent director.

Hamid Erfanian and Bradley Radoff Appointed to Enzo Biochem's Board of Directors

Enzo Biochem, Inc. (ENZ) CEO Hamid Erfanian on Q1 2022 Results - Earnings Call Transcript

Conference call and live webcast scheduled for today, Wednesday, December 15, 2021 at 4:30 pm (ET)

News for Enzo Biochem Stock (ENZ)